The feasibility of ovarian tissue cryopreservation in selected females after hematopoietic stem cell transplantation Authors: Jiaojiao Cheng, Juan Du, Muqing Gu, Xiangyan Ruan, Fengyu Jin, Jing Jin, Zecheng Wang, Yurui Wu, Qin Zhou, Yanqiu Li, Yanglu Li, Lingling Jiang, Mingzhen Zhang, Anming Liu, Yuejiao Wang, Alfred O. Mueck Published: 2026 ABSTRACT We evaluated whether ovarian tissue cryopreservation (OTC) is a viable option for girls and young women who have already undergone hematopoietic stem cell transplantation (HSCT). We enrolled 142 patients who underwent OTC either before or after HSCT. Participants were categorized into three groups: “after HSCT group” (n = 16), “no-chemo group” before OTC (n = 75), and “chemo group” before OTC (n = 51). The after HSCT cohort had a mean age of 12.06 years at OTC, with half being pre-pubertal. Comparative analysis across age (0-12 and 13-24 years) revealed that the after-HSCT group consistently presented with significantly elevated FSH and diminished AMH levels relative to the no-chemo group. Ovarian volume per ovary was also markedly reduced in the after-HSCT group compared to the no-chemo group across all ages. Crucially, the estimated total follicle count per ovary was significantly lower in the after-HSCT group than in both pre-HSCT groups among 0–12 years, and versus the “no-chemo group” in 13–24 years. This confirms pre-HSCT fertility preservation as the paramount strategy. However, OTC post-HSCT emerges as a viable salvage option for carefully selected patients, underscoring the need for long-term follow-up to identify candidates and expand fertility possibilities in survivorship care. Introduction Hematopoietic stem cell transplantation (HSCT) is an established therapeutic modality for over 30 malignant and non-malignant conditions, with approximately 50,000 procedures performed worldwide each year [1]. With the long-term survival rate of HSCT recipients steadily improving [2], preserving their quality of life, particularly ovarian function and fertility, has become a paramount concern for survivors. Unfortunately, the risk of infertility following the intensive conditioning regimens required for HSCT exceeds 80% [3, 4]. Ovarian failure following HSCT is notably more severe, occurs with higher frequency and earlier onset, and has a lower likelihood of recovery compared to other treatments [5]. This is starkly evidenced by large cohort studies showing that only 0.6% of women conceived post-HSCT [6, 7], underscoring the profound gonadotoxicity primarily associated with the intensity and types of conditioning [8]. For many young cancer survivors, the loss of fertility can be as devastating as the cancer diagnosis itself, profoundly impacting their quality of life and psychological well-being [9]. Premature ovarian insufficiency (POI), the most common late-effect complication of HSCT, profoundly impacts long-term quality of life. Only a small minority (<5%) of these patients experience transient ovarian function recovery after HSCT before progressing to early menopause [5]. The sequelae of POI and estrogen deficiency are extensive, encompassing vasomotor symptoms, neuropsychological disturbances, arthralgia, sexual dysfunction, and irreversible loss of reproductive capacity—all of which detrimentally affect quality of life. Furthermore, premature estrogen deprivation not only impedes the development of secondary sexual characteristics but also increases the long-term risk of osteoporosis, cardiovascular disease, and dementia, conditions frequently observed in this population [5]. Addressing this issue remains a critical unmet need during survivorship. In response, major professional societies, including the American Academy of Pediatrics [10], the American Society of Clinical Oncology [11], the Children’s Oncology Group (COG) [12, 13], and the American Society of Reproductive Medicine (ASRM) [14], and the European Society of Human Reproduction and Embryology (ESHRE) [15] unanimously recommend early discussions about fertility, irrespective of the risk profile, before treatment begins. Consequently, fertility preservation (FP) has emerged as a central component of contemporary cancer management, especially for women who wish to preserve childbearing and endocrine functions [9, 16]. Evidence still exists to suggest gaps in access to infertility risk assessment and to FP procedures for pediatric patients. Not all hospitals have the capability for a full FP program, but all patients should be appropriately counseled and then referred to high-volume centers for procedures if indicated. As the availability of FP options and research outcomes improves, pediatric patients may look forward to fertility restorations as future adults [17]. Ovarian tissue cryopreservation (OTC) and transplantation (OTCT) have emerged as a pivotal FP strategy, uniquely for pre-pubertal girls and cases where cancer treatment cannot be delayed [11, 14, 18]. While the theoretical risk of malignant cell reintroduction exists for hematologic malignancies, current guidelines permit OTC after induction chemotherapy confirms complete remission [19, 20]. Its efficacy is supported by numerous successful live births following transplantation after HSCT [21–25]. Importantly, recent guidelines from the ESHRE explicitly state that prior exposure to low-gonadotoxic chemotherapy does not preclude OTC [15]. This aligns with the evolving concept of comprehensive post-treatment care, which includes assessing ovarian reserve about one year after therapy to guide secondary FP or manage POI [26]. This assessment relies on key indicators, including elevated follicle-stimulating hormone (FSH), low anti-mullerian hormone (AMH), and reduced antral follicle count [27, 28]. However, existing research and clinical practice have predominantly focused on performing OTC before HSCT. In contrast, the feasibility of FP for women who have already undergone HSCT remains a significant and largely unaddressed knowledge gap. This specific patient population includes, for instance, those requiring a second HSCT due to graft failure or individuals found to have retained some degree of ovarian function during long-term follow-up. Challenging this assumption, our preliminary clinical observations have identified the presence of active follicles in ovarian tissues from a subset of girls after HSCT [29]. Therefore, this study was designed to systematically evaluate the feasibility of OTC after HSCT by comparing ovarian reserve parameters—including age, AMH, FSH, ovarian volume per ovary, and the estimated total follicle count per ovary—among three distinct groups: patients undergoing OTC before HSCT without prior chemotherapy, those before HSCT with chemotherapy, and those after HSCT. This comparative analysis aims, for the first time, to provide crucial evidence to guide clinical decision-making and offer a potential avenue of hope for this unique patient population, who standard FP strategies have traditionally overlooked. Materials and methods Patient selection and study design This was a single-center, retrospective cohort study conducted at the Ovarian Cryobank of Beijing Obstetrics and Gynecology Hospital, Capital Medical University, between August 2023 and July 2025. Inclusion criteria were: (1) female patients who underwent OTC at our center; (2) age between 0 and 24 years; (3) either planned to undergo HSCT or had already undergone HSCT; and (4) absence of underlying diseases that directly compromise ovarian follicle density or function. Exclusion criteria were: (1) prior history of ovarian surgery or oophorectomy; (2) incomplete medical records or missing key data; and (3) refusal to provide informed consent for participation in the study. This study enrolled 142 patients who underwent OTC either before or after HSCT at our center. Participants were categorized into three groups: the “after-HSCT group” (n = 16), who underwent OTC following HSCT; the “no-chemo group” (n = 75), who underwent OTC before HSCT without any prior chemotherapy; and the “chemo group” (n = 51), who underwent OTC before HSCT after having received chemotherapy. The study design first involved an analysis of the clinical characteristics of the after-HSCT group. Subsequently, all patients were stratified into two age cohorts (0 ~ 12 years and 13 ~ 24 years). Within each cohort, after confirming no significant differences in age among the three groups, we compared the following pre-OTC parameters: AMH levels, FSH levels, unilateral ovarian volume, and the estimated total follicle count per ovary (Fig. 1).Fig. 1Design of this study.OTC ovarian tissue cryopreservation, HSCT hematopoietic stem cell transplantation, AMH Anti-Müllerian Hormone, FSH follicle-stimulating hormone. Design of this study. OTC ovarian tissue cryopreservation, HSCT hematopoietic stem cell transplantation, AMH Anti-Müllerian Hormone, FSH follicle-stimulating hormone. The diagnosis of patients Patients in the OTC after-HSCT group (n = 16) were diagnosed with the following conditions: primary immunodeficiency (n = 2), dermatomyositis (n = 1), aplastic anemia (AA) (n = 5), acute myeloid leukemia (AML) (n = 3), lymphoma with hemophagocytic syndrome (n = 1), chronic active Epstein-Barr virus infection-associated hemophagocytic syndrome (n = 1), hemophagocytic syndrome (n = 1), acute non-lymphocytic leukemia with neuroblastoma (n = 1), and T-lymphoblastic lymphoma (n = 1). Group Composition: hematologic malignancies constituted 37.50% (n = 6), hematologic non-malignancies 31.25% (n = 5), and other non-malignancies 31.25% (n = 5). Patients in the no-chemo group (n = 75) were diagnosed with: AA (n = 28), chronic active Epstein-Barr virus infection (n = 10), Glanzmann thrombasthenia (n = 6), mucopolysaccharidosis (n = 6), hemophagocytic syndrome (n = 5), thalassemia (n = 4), Niemann-Pick disease (n = 4), Shwachman-Diamond syndrome (n = 4), myelodysplastic syndrome (MDS) (n = 3), very early-onset inflammatory bowel disease (n = 2), pyruvate kinase deficiency (n = 1), globoid cell leukodystrophy (n = 1), and primary immunodeficiency (n = 1). Group Composition: was 54.67% (n = 41) hematologic non-malignancies and 45.33% (n = 34) other non-malignancies. Patients in the chemo group (n = 51) were diagnosed with: leukemia (n = 38), hemophagocytic syndrome (n = 3), Hodgkin lymphoma (n = 2), non-Hodgkin lymphoma (n = 1), NK/T-cell lymphoma (n = 1), T-lymphoblastic lymphoma (n = 1), anaplastic large cell lymphoma (n = 1), chronic active Epstein-Barr virus infection (n = 2), AA (n = 1), and MDS (n = 1). Group Composition: 86.28% (n = 44) hematologic malignancies, 3.92% (n = 2) hematologic non-malignancies, and 9.80% (n = 5) other non-malignancies. The composition of the three disease categories (hematologic malignancies, hematologic non-malignancies, and other non-malignancies) in the no-chemo, chemo, and after-HSCT groups (Fig. 2).Fig. 2The composition of the three disease categories (hematologic malignancies, hematologic non-malignancies, and other non-malignancies) in the no-chemo, chemo, and after-HSCT groups. The composition of the three disease categories (hematologic malignancies, hematologic non-malignancies, and other non-malignancies) in the no-chemo, chemo, and after-HSCT groups. FP counseling, ovarian tissue biopsy and freezing Prior to OTC, all 142 patients underwent comprehensive FP counseling, ovarian reserve assessment and surgical risk evaluation. For patients with hematologic malignancies, a rigorous clinical evaluation was performed in accordance with current international guidelines [30]. This process included confirmation of minimal residual disease status and a multidisciplinary team discussion. All patients and their families were thoroughly counseled regarding the potential risk of reintroducing malignant cells with OTCT. Regarding the choice of FP method, all available options were discussed with patients and their families according to age and pubertal status. For postpubertal patients, this included discussions of hormonal stimulation for oocyte cryopreservation and, when applicable, embryo cryopreservation. OTC was ultimately chosen based on a combination of factors, including the urgency of HSCT, patient preference, and other clinical considerations. Written informed consent was obtained from all participants or their legal guardians following these discussions. This procedure is especially important if reliable molecular markers are not yet available to exclude the presence of malignant cells in ovarian tissue, as is the case, for example, in patients with leukemia. The ovarian tissue collection procedure was successful in all cases, with no complications reported, and it did not interfere with subsequent treatments. The ovarian tissue was cryopreserved using the internationally recognized standard slow-freezing protocol [20, 21]. Evaluation of FSH and AMH before OTC The levels of FSH in serum before OTC were determined by the Centaur automatic chemiluminescence immunoassay produced by Bayer Company in the United States. AMH was determined using the AMH kit (Guangzhou Kangrun Company, China) by enzyme-linked immunosorbent assay. The intra-assay and inter-assay errors were 3.3% and 6.7%, respectively [31]. Evaluation of ovarian volume per ovary The ovarian volume is calculated as (π/6) × long diameter × short diameter × short diameter [32]. After ovarian tissue retrieval, the long and short diameters were measured using a straight ruler. Evaluation of follicle density and total follicle count per ovary Evaluation of follicle density was performed on a 2-mm ovarian tissue biopsy stained with Calcein-AM, in accordance with our prior methodology [33]. The total follicle count per unilateral ovary was derived by extrapolating the biopsy density to the entire cryopreserved ovarian cortex. The calculation was as follows: Total Follicle Count = (follicle density/π) × (number of cryopreserved cortical strips) × (4 mm × 8 mm). All follicle counts were performed by a single, experienced laboratory technician who has received specialized training in ovarian follicle assessment and has over ten years of experience in this field. To ensure consistency and reliability, the counting protocol was strictly standardized, and periodic intra-operator reliability checks were performed. The technician was blinded to the patients’ clinical information during the counting process to minimize potential bias. Statistical analysis Statistical analyses were performed using SPSS 23.0 (IBM, Chicago, IL, USA). The normality of the data distribution was assessed with the Kolmogorov-Smirnov test. For data conforming to a normal distribution, one-way ANOVA was applied for inter-group comparisons, followed by the LSD post hoc test for pairwise comparisons. For data that did not follow a normal distribution, the Kruskal-Wallis non-parametric test was employed. Graphical representations were generated using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). A P-value of less than 0.05 was considered statistically significant, with specific thresholds denoted as *P < 0.05, **P < 0.01, ***P < 0.001. Sample size justification No formal sample size calculation was performed prior to this study, as this was an exploratory, retrospective analysis of a novel and rare patient population (females undergoing OTC after HSCT). The sample size was determined by the number of eligible patients who met the inclusion criteria during the study period. Future prospective studies should consider power calculations based on the effect sizes observed in this cohort. Data management All patients who met the inclusion criteria were included in the study; no patients were excluded after enrollment. Complete data for age and AMH were available for all 142 patients. In the after-HSCT group, two patients had missing data for specific variables. One patient underwent bilateral ovarian tissue biopsy rather than unilateral oophorectomy; therefore, ovarian volume per ovary and estimated total follicle count could not be assessed for this patient. Another patient had missing detailed conditioning regimen information due to incomplete medical records from the referring institution. Specifically, the patient with missing ovarian data was excluded from the comparisons of ovarian volume per ovary and estimated total follicle count, and the patient with missing chemotherapy data was excluded from subgroup analyses requiring detailed regimen information. Results Patients’ characteristics Between August 2023 and July 2025, a total of 142 patients underwent OTC at our center either before or after HSCT. The baseline characteristics of all enrolled patients are summarized in Table 1. This cohort included 16 patients who underwent OTC after HSCT, and their characteristics are summarized in Table 2. The primary indication for OTC was the need for a second HSCT in two patients, while the remaining 14 patients underwent the procedure for the purpose of future fertility and ovarian endocrine function preservation. The mean interval from HSCT to OTC was 36.5 months (range: 11–111 months). The mean age at OTC was 12.06 years (range: 4–21 years). At the time of the procedure, 8 patients (50%) were pre-pubertal, and 8 (50%) were post-menarche. The laparoscopic surgery was well-tolerated, with no acute or chronic complications reported.Table 1Baseline characteristics of all enrolled patients stratified by group.No-chemo group (N = 75)Chemo group (N = 51)After-HSCT group (N = 16)Age group, N0-12 yearsN = 64N = 26N = 1013-24 yearsN = 11N = 25N = 6Age/years, median (range)8 (0.5–21)10 (4–24)10.5 (4–21)Diagnosis, N (%)Hematologic malignancies044 (86.28%)6 (37.5%)Hematologic non-malignancies41 (54.67%)2 (3.92%)5 (31.25%)Other non-malignancies34 (45.33%)5 (9.80%)5 (31.25%)Conditioning regimen, N (%)*RICNANA7 (46.67%)MACNANA8 (53.33%)AMH/ng/ml, median (range)2.27 (0.06–10.89)1.44 (0.06–3.94)0.06 (0.06–10.00)FSH/IU/L, median (range)3.38 (0.20–11.58)3.91 (0.20–138.30)8.08 (1.17–22.84)Ovarian volume per ovary/mm3, median (range)2371.50 (84.00–11775.00)1377.00 (94.00–4287.00)952.00 (264.00–2708.00)Data are presented as n (%) or median (range).*one patient in the after-HSCT group had missing detailed conditioning regimen information due to incomplete medical records from the referring institution.RIC reduced-Intensity Conditioning, MAC Myeloablative Conditioning, AMH Anti-Müllerian Hormone, FSH Follicle-Stimulating Hormone, NA Not ApplicableTable 2Patients’ characteristics of OTC after HSCT.NumberDiagnosisAge at OTC (years)Pre-pubertal at OTCConditioning RegimensLong diameter (mm)Short diameter (mm)Ovarian volume (mm3)Estimated total follicle count per ovaryThe time from HSCT to OTC (months)The need for a second HSCTAMH (ng/ml)FSH (IU/L)1chronic active Epstein-Barr virus infection-associated hemophagocytic syndrome12YES*25764197824NO0.067.812hemophagocytic syndrome12YESRIC: VP16+Bu+FLu+ATG+Cy1813159218,000100NO0.068.353T-lymphoblastic lymphoma21NOMAC: Ara-C + IDA + TBI+Cy+ATG+MeCCNu2989718270NO0.0615.324Lymphoma with hemophagocytic syndrome11YESRIC: Bu+Cy+VP1627101413569912YES0.0622.845Acute non-lymphocytic leukemia with neuroblastoma15NORIC: Bu+Cy+ATG +MeCCNu23101204459111NO0.0688.906AML10YESMAC: Bu+Cy+ATG22756410,46630NO0.164.87AML13NOMAC: Bu+CTX + ATG206377315939NO0.060.618AML18NOMAC: CCNU + 2-CdA+Ara-C + DEX + G-CSF+Bu+CTX + ATG2813247624548NO0.168.369AA9NOMAC: Bu+Cy+Flu+ATG229933448431NO0.0616.2310AA9NORIC: Flu+Cy+ATG3215376812,00037NO105.3411AA12YESRIC: Ara-C+Bu+Flu+Cy+ATG3210167545936NO0.0610.6912AA15NOMAC: Bu+Flu+CTX + ATG23152708658319NO0.06–13AA19NOMAC: BU + CY + FLU + ATG––––50NO0.0622.7614primary immunodeficiency4YESMAC: Bu+ATG+Flu+Cy20751312,00020NO0.067.7215primary immunodeficiency5YESRIC: ALG+Flu+CTX + MEL22756449,00025NO1.83.0216dermatomyositis8YESRIC: CTX+Flu+ATG14626443,29770YES0.811.17*The number one patient had missing detailed conditioning regimen information due to incomplete medical records from the referring institution.OTC ovarian tissue cryopreservation, HSCT Hematopoietic Stem Cell Transplantation, AMH anti-mullerian hormone, FSH follicle-stimulating hormone, AML acute myeloid leukemia, AA aplastic anemia, RIC reduced-intensity conditioning, MAC myeloablative conditioning, VP16 Etoposide, Bu Busulfan, FLu Fludarabine, ATGAnti-thymocyte Globulin, Cy Cyclophosphamide, Ara-C Cytarabine, IDA Idarubicin, TBITotal Body Irradiation; MeCCNu Semustine, 2-CdA Cladribine, CCNU Lomustine, DEX Dexamethasone, G-CSF Granulocyte Colony-Stimulating Factor, CTX Cyclophosphamide, ALGAnti-lymphocyte Globulin, MEL Melphalan. Table 1Baseline characteristics of all enrolled patients stratified by group.No-chemo group (N = 75)Chemo group (N = 51)After-HSCT group (N = 16)Age group, N0-12 yearsN = 64N = 26N = 1013-24 yearsN = 11N = 25N = 6Age/years, median (range)8 (0.5–21)10 (4–24)10.5 (4–21)Diagnosis, N (%)Hematologic malignancies044 (86.28%)6 (37.5%)Hematologic non-malignancies41 (54.67%)2 (3.92%)5 (31.25%)Other non-malignancies34 (45.33%)5 (9.80%)5 (31.25%)Conditioning regimen, N (%)*RICNANA7 (46.67%)MACNANA8 (53.33%)AMH/ng/ml, median (range)2.27 (0.06–10.89)1.44 (0.06–3.94)0.06 (0.06–10.00)FSH/IU/L, median (range)3.38 (0.20–11.58)3.91 (0.20–138.30)8.08 (1.17–22.84)Ovarian volume per ovary/mm3, median (range)2371.50 (84.00–11775.00)1377.00 (94.00–4287.00)952.00 (264.00–2708.00)Data are presented as n (%) or median (range).*one patient in the after-HSCT group had missing detailed conditioning regimen information due to incomplete medical records from the referring institution.RIC reduced-Intensity Conditioning, MAC Myeloablative Conditioning, AMH Anti-Müllerian Hormone, FSH Follicle-Stimulating Hormone, NA Not Applicable Baseline characteristics of all enrolled patients stratified by group. Data are presented as n (%) or median (range). *one patient in the after-HSCT group had missing detailed conditioning regimen information due to incomplete medical records from the referring institution. RIC reduced-Intensity Conditioning, MAC Myeloablative Conditioning, AMH Anti-Müllerian Hormone, FSH Follicle-Stimulating Hormone, NA Not Applicable Table 2Patients’ characteristics of OTC after HSCT.NumberDiagnosisAge at OTC (years)Pre-pubertal at OTCConditioning RegimensLong diameter (mm)Short diameter (mm)Ovarian volume (mm3)Estimated total follicle count per ovaryThe time from HSCT to OTC (months)The need for a second HSCTAMH (ng/ml)FSH (IU/L)1chronic active Epstein-Barr virus infection-associated hemophagocytic syndrome12YES*25764197824NO0.067.812hemophagocytic syndrome12YESRIC: VP16+Bu+FLu+ATG+Cy1813159218,000100NO0.068.353T-lymphoblastic lymphoma21NOMAC: Ara-C + IDA + TBI+Cy+ATG+MeCCNu2989718270NO0.0615.324Lymphoma with hemophagocytic syndrome11YESRIC: Bu+Cy+VP1627101413569912YES0.0622.845Acute non-lymphocytic leukemia with neuroblastoma15NORIC: Bu+Cy+ATG +MeCCNu23101204459111NO0.0688.906AML10YESMAC: Bu+Cy+ATG22756410,46630NO0.164.87AML13NOMAC: Bu+CTX + ATG206377315939NO0.060.618AML18NOMAC: CCNU + 2-CdA+Ara-C + DEX + G-CSF+Bu+CTX + ATG2813247624548NO0.168.369AA9NOMAC: Bu+Cy+Flu+ATG229933448431NO0.0616.2310AA9NORIC: Flu+Cy+ATG3215376812,00037NO105.3411AA12YESRIC: Ara-C+Bu+Flu+Cy+ATG3210167545936NO0.0610.6912AA15NOMAC: Bu+Flu+CTX + ATG23152708658319NO0.06–13AA19NOMAC: BU + CY + FLU + ATG––––50NO0.0622.7614primary immunodeficiency4YESMAC: Bu+ATG+Flu+Cy20751312,00020NO0.067.7215primary immunodeficiency5YESRIC: ALG+Flu+CTX + MEL22756449,00025NO1.83.0216dermatomyositis8YESRIC: CTX+Flu+ATG14626443,29770YES0.811.17*The number one patient had missing detailed conditioning regimen information due to incomplete medical records from the referring institution.OTC ovarian tissue cryopreservation, HSCT Hematopoietic Stem Cell Transplantation, AMH anti-mullerian hormone, FSH follicle-stimulating hormone, AML acute myeloid leukemia, AA aplastic anemia, RIC reduced-intensity conditioning, MAC myeloablative conditioning, VP16 Etoposide, Bu Busulfan, FLu Fludarabine, ATGAnti-thymocyte Globulin, Cy Cyclophosphamide, Ara-C Cytarabine, IDA Idarubicin, TBITotal Body Irradiation; MeCCNu Semustine, 2-CdA Cladribine, CCNU Lomustine, DEX Dexamethasone, G-CSF Granulocyte Colony-Stimulating Factor, CTX Cyclophosphamide, ALGAnti-lymphocyte Globulin, MEL Melphalan. Patients’ characteristics of OTC after HSCT. *The number one patient had missing detailed conditioning regimen information due to incomplete medical records from the referring institution. OTC ovarian tissue cryopreservation, HSCT Hematopoietic Stem Cell Transplantation, AMH anti-mullerian hormone, FSH follicle-stimulating hormone, AML acute myeloid leukemia, AA aplastic anemia, RIC reduced-intensity conditioning, MAC myeloablative conditioning, VP16 Etoposide, Bu Busulfan, FLu Fludarabine, ATGAnti-thymocyte Globulin, Cy Cyclophosphamide, Ara-C Cytarabine, IDA Idarubicin, TBITotal Body Irradiation; MeCCNu Semustine, 2-CdA Cladribine, CCNU Lomustine, DEX Dexamethasone, G-CSF Granulocyte Colony-Stimulating Factor, CTX Cyclophosphamide, ALGAnti-lymphocyte Globulin, MEL Melphalan. Subgroup analysis of after-HSCT patients by conditioning regimen To explore the impact of conditioning regimen intensity on ovarian reserve, we compared patients in the after-HSCT group who received reduced-intensity conditioning (RIC) versus myeloablative conditioning (MAC). No significant difference was observed in age between the two subgroups (mean ± SEM: 10.29 ± 1.23 vs. 12.86 ± 2.18 years, P = 0.324). Ovarian volume per ovary did not differ significantly between the RIC and MAC groups (mean ± SEM: 1497.14 ± 427.67 mm³ vs. 1220.29 ± 364.39 mm³, P = 0.522). The estimated total follicle count per ovary was lower in patients who received MAC compared to those who received RIC (mean ± SEM: 5288.43 ± 1767.79 vs. 18416.29 ± 7563.09); however, this difference did not reach statistical significance (P = 0.137), likely due to the small sample size within each subgroup (Fig. 3).Fig. 3Subgroup analysis of age, ovarian volume per ovary and estimated total follicle count in after-HSCT patients stratified by conditioning regimen (RIC vs MAC).a Age at OTC; b Ovarian volume per ovary; c Estimated total follicle count. OTC ovarian tissue cryopreservation, RIC reduced-intensity conditioning, MAC myeloablative conditioning. Subgroup analysis of age, ovarian volume per ovary and estimated total follicle count in after-HSCT patients stratified by conditioning regimen (RIC vs MAC). a Age at OTC; b Ovarian volume per ovary; c Estimated total follicle count. OTC ovarian tissue cryopreservation, RIC reduced-intensity conditioning, MAC myeloablative conditioning. The comparisons of age Among children aged 0–12 years, no significant differences were observed in age across the three groups (no-chemo vs. Chemo vs. after-HSCT, mean ± SEM: 6.96 ± 0.44 vs. 7.58 ± 0.53 vs. 9.20 ± 0.90 years, P = 0.146). Among children aged 13– 24 years, no significant differences in age were observed among the three groups (16.64 ± 1.05 vs. 18.28 ± 0.74 vs. 16.83 ± 1.22 years, P = 0.378) (Fig. 4).Fig. 4The comparisons between the three groups about the age among the 0 – 12years olds and 13–24 years old.a 0–12 years old; b 13–24 years old. OTC ovarian tissue cryopreservation, HSCT hematopoietic stem cell transplantation. The comparisons between the three groups about the age among the 0 – 12years olds and 13–24 years old. a 0–12 years old; b 13–24 years old. OTC ovarian tissue cryopreservation, HSCT hematopoietic stem cell transplantation. The evaluation of FSH and AMH before OTC About FSH, among children aged 0–12 years, the after-HSCT group exhibited a significantly higher FSH (mean ± SEM: 8.80 ± 2.05 IU/L) compared to the no-chemo group (3.75 ± 0.31 IU/L, P = 0.014) and chemo group (6.59 ± 3.00 IU/L, P = 0.024). Among children aged 13 ~ 24 years, the after-HSCT (mean ± SEM: 27.19 ± 15.86 IU/L, P = 0.033) and chemo groups (22.19 ± 8.42 IU/L, P = 0.027) exhibited a significantly higher FSH compared to the no-chemo group (3.37 ± 0.87 IU/L). (Fig. 5a, a’).Fig. 5Comparison of FSH and AMH levels among three groups, stratified by age groups (0–12 years old and 13–24 years old).a FSH in 0–12 years-old; a' FSH in 13–24 years old; b AMH in 0–12 years old; b' AMH in 13–24 years old. HSCT hematopoietic stem cell transplantation, AMH Anti-Müllerian Hormone, FSH follicle-stimulating hormone. *P<0.05, **P<0.01, ***P<0.001. Comparison of FSH and AMH levels among three groups, stratified by age groups (0–12 years old and 13–24 years old). a FSH in 0–12 years-old; a' FSH in 13–24 years old; b AMH in 0–12 years old; b' AMH in 13–24 years old. HSCT hematopoietic stem cell transplantation, AMH Anti-Müllerian Hormone, FSH follicle-stimulating hormone. *P<0.05, **P<0.01, ***P<0.001. About AMH, among children aged 0–12 years, the after-HSCT (mean ± SEM: 1.31 ± 0.98, P = 0.000) and chemo groups (1.34 ± 0.21 ng/ml, P = 0.001) exhibited a significantly lower AMH compared to the no-chemo group (3.10 ± 0.30 ng/ml). Among children aged 13–24 years, the after-HSCT group exhibited a significantly lower AMH (mean ± SEM: 0.08 ± 0.02 ng/ml) compared to the no-chemo group (2.95 ± 0.70 ng/ml, P = 0.000) and chemo group (1.26 ± 0.26 ng/ml, P = 0.019). (Fig. 5b, b’). The comparisons of ovarian volume per ovary and the estimated total follicle count per ovary About ovarian volume per ovary, among children aged 0–12 years, the after-HSCT (mean ± SEM: 845.71 ± 186.24mm3, P = 0.006) and chemo groups (mean ± SEM: 1354.88 ± 253.24mm3, P = 0.020) exhibited a significantly lower compared to the no-chemo group (2306.77 ± 258.72). Among children aged 13–24 years, the after-HSCT (mean ± SEM: 1547.20 ± 448.85 mm3, P = 0.001) and chemo groups (mean ± SEM: 2415.10 ± 307.15 mm3, P = 0.015) exhibited a significantly lower value compared to the no-chemo group (3704.56 ± 392.02 mm3). (Fig. 6a, a’).Fig. 6Comparison of ovarian volume per ovary and estimated total follicle count per ovary among three groups, stratified by age groups (0–12 years old and 13–24 years old).a Ovarian volume per ovary in 0–12 years old; a' Ovarian volume per ovary in 13–24 years old; b Estimated total follicle count per ovary in 0–12 years old; b' Estimated total follicle count per ovary in 13–24 years old. HSCT hematopoietic stem cell transplantation. *P<0.05, **P<0.01. Comparison of ovarian volume per ovary and estimated total follicle count per ovary among three groups, stratified by age groups (0–12 years old and 13–24 years old). a Ovarian volume per ovary in 0–12 years old; a' Ovarian volume per ovary in 13–24 years old; b Estimated total follicle count per ovary in 0–12 years old; b' Estimated total follicle count per ovary in 13–24 years old. HSCT hematopoietic stem cell transplantation. *P<0.05, **P<0.01. About the estimated total follicle count per ovary, among children aged 0–12 years, the after-HSCT group (mean ± SEM: 19065.43 ± 7323.70) exhibited a significantly lower count compared to the chemo group (mean ± SEM: 61198.62 ± 13324.82, P = 0.028) and the no-chemo group (mean ± SEM: 59332.77 ± 8516.77, P = 0.004). Among children aged 13–24 years, the after-HSCT group (mean ± SEM: 2105.60 ± 1253.49) exhibited a significantly lower value compared to the no-chemo group (mean ± SEM: 20620.33 ± 8750.11, P = 0.039). (Fig. 6b, b’). Representative images of unilateral ovaries and follicular activity from the no-chemo, chemo, and after-HSCT groups are shown in Fig. 7.Fig. 7Representative images of unilateral ovaries and follicular activity from the three groups.a Unilateral ovary from a 13-year-old patient with AA in the no-chemo group; b Follicular activity from the same patient; c Unilateral ovary from a 10-year-old patient with MDS in the chemo group; d Follicular activity from the same patient; e Unilateral ovary from a 15-year-old patient with AA in the after-HSCT group; f Follicular activity from the same patient. AA Aplastic Anemia, MDS Myelodysplastic Syndromes, HSCT hematopoietic stem cell transplantation. Representative images of unilateral ovaries and follicular activity from the three groups. a Unilateral ovary from a 13-year-old patient with AA in the no-chemo group; b Follicular activity from the same patient; c Unilateral ovary from a 10-year-old patient with MDS in the chemo group; d Follicular activity from the same patient; e Unilateral ovary from a 15-year-old patient with AA in the after-HSCT group; f Follicular activity from the same patient. AA Aplastic Anemia, MDS Myelodysplastic Syndromes, HSCT hematopoietic stem cell transplantation. Discussion This study, through a systematic comparison of ovarian reserve in patients before (with or without prior chemotherapy) and after HSCT, demonstrates that OTC remains a technically feasible FP method for a subset (approximately 1%) of female patients even after undergoing HSCT. Although post-HSCT patients exhibited the most severe impairment across all ovarian reserve parameters assessed, the consistent presence of viable follicles in the ovarian tissue of all 16 patients in the after-HSCT OTC group indicates the potential for “salvage” FP in this specific population. In the chemotherapy group, pre-pubertal girls (aged 0–12 years) primarily showed significantly reduced AMH levels and markedly decreased ovarian volume, yet without a statistically significant difference in estimated follicle count per ovary. In adolescents and young adults (aged 13–24 years), this group displayed significantly elevated FSH levels and significantly reduced ovarian volume, again without a statistically significant reduction in estimated follicle count per ovary. This pattern suggests that chemotherapy primarily damages the growing follicle pool, leading to decreased AMH secretion, and injures the ovarian stroma and vascular supply, resulting in reduced ovarian volume—an early morphological warning sign. However, it does not appear to inflict devastating damage upon the dormant primordial follicle reserve. This aligns with findings from Houeis et al., indicating that low-dose alkylating agents primarily affect secondary follicles and increase fibrotic trends without significantly harming primordial follicle density [34]. The observed stromal damage is consistent with reports of microvascular changes, including vessel wall thickening, hyalinization, and focal fibrosis in chemotherapy-exposed ovaries [35]. The particular sensitivity of AMH, secreted by small antral follicles, to chemotherapy is well-documented [36]. The absence of significant FSH elevation in the 0-12 year age group is likely attributable to the immaturity of the hypothalamic-pituitary-ovarian (HPO) axis and its feedback mechanisms, or because the ovarian insult had not yet reached the threshold required to trigger a significant FSH rise. In contrast, the mature HPO axis in the 13–24 year group makes elevated FSH a clear marker of diminished ovarian reserve [27]. In contrast, the after HSCT group demonstrated profound ovarian impairment. These patients exhibited the highest FSH levels, the lowest AMH levels, and the smallest ovarian volumes across all age groups. Most critically, they also showed a significant decline in the estimated total follicle count per ovary. This clearly indicates that the conditioning regimens for HSCT inflict comprehensive damage to ovarian function, not only exacerbating the injury to growing follicles and ovarian stroma caused by chemotherapy but also directly and severely depleting the primordial follicle reserve. The underlying mechanisms likely involve conditioning-induced massive primordial follicle apoptosis or over-activation, coupled with significant stromal micro-vascular damage and fibrosis [35, 37, 38]. We initially attempted within the after-HSCT group a subgroup analysis on the difference in follicle density comparing patients with malignant versus non-malignant diagnoses. However, we identified a significant age difference (P < 0.05). Since age is a well-established major confounding factor for ovarian reserve parameters such as ovarian volume and follicle count, a direct comparison without adjusting for age would yield potentially misleading results. So, an age-adjusted analysis or age-matched comparison would be required. Unfortunately, due to the very small sample size within these subgroups, such statistical adjustments were not feasible, and any observed differences could not be reliably attributed to the disease type rather than the age disparity. We strongly recommend making every effort to perform FP, such as OTC, before HSCT to preserve both fertility and endocrine function. This represents the most effective strategy for securing the highest quality ovarian tissue. The safety of OTC before HSCT is supported by studies reporting no periprocedural complications in children and adolescents [39, 40]. Our data robustly support that OTC retains significant value even for patients who have received chemotherapy and achieved complete remission before conditioning regimens of HSCT, as their primordial follicle reserve may remain partially intact. This conclusion is consistent with multiple international studies [41–43]. Therefore, prior exposure to chemotherapy should not automatically disqualify patients from undergoing OTC. For patients who missed the opportunity for FP before HSCT, our findings confirm that they should not be universally excluded from consideration. It is crucial to establish long-term, regular gynecological endocrine follow-up for after-HSCT survivors, including annual monitoring of ovarian function and pubertal development [26, 44]. Regular assessments allow for the timely initiation of hormone replacement therapy (HRT) when indicated [44, 45]. The rapid decline in ovarian function after-HSCT underscores the urgency; FSH rises significantly (in girls ≥10 years), AMH decreases, and the incidence of POI reaches 26.92%, 47.44%, and 70.18% at 1, 2, and 3 years after-HSCT, respectively [46]. The window for intervention is narrow, as evidenced by a study where 40% of girls transplanted before age five experienced menarche, but 40% of those subsequently progressed to POI within five years [44]. In our study, the mean interval from HSCT to OTC was 36.5 months. Notably, one patient who had undergone HSCT exhibited a marked increase in FSH levels, from 16.12 IU/L to 88.9 IU/L, within 2 months. After comprehensive counseling and with informed consent, she proceeded to OTC, motivated by strong patient and family willingness. An average of 5 follicles was found in a 2 mm cortex biopsy, highlighting that patient psychology and hope for the future must also be cared for [47]. Consequently, for patients showing signs of residual ovarian function during follow-up (e.g., detectable AMH, spontaneous menstruation), and particularly for those facing a second HSCT due to graft failure, proactive assessment and counseling regarding salvage FP options should be offered [5]. This study has limitations. Its single-center design may introduce selection bias. Furthermore, while we were able to document the specific conditioning regimens for patients in the after-HSCT group, comprehensive data on cumulative chemotherapy doses—including cyclophosphamide equivalent dose (CED)—were not available for either the chemo group or the after-HSCT group. This precluded a quantitative dose-response analysis and may affect the precise interpretation of the degree of ovarian damage attributable to treatment intensity. Additionally, while we assessed ovarian reserve using AMH, FSH, and follicle counts, we acknowledge that single AMH measurements in prepubertal patients have limited predictive value for future fertility, as longitudinal measurements are more informative [48]. Furthermore, detailed Tanner staging data, which would provide a more comprehensive assessment of pubertal development, were not available for all prepubertal patients due to the retrospective design of this study. Future large-scale, multicenter, prospective studies are warranted to address these limitations. Such studies should incorporate detailed treatment exposure data, longitudinal hormone monitoring, and standardized pubertal staging to better characterize ovarian function and identify key factors influencing the success of OTC after HSCT. Long-term follow-up of these patients is also essential to evaluate the ultimate reproductive and endocrine benefits of OTC and the outcomes of subsequent ovarian tissue transplantation. The core findings of this study: firstly, HSCT poses a severe threat to ovarian function, making FP before HSCT an unequivocal clinical priority. Secondly, this study provides a new perspective for FP after HSCT, demonstrating that OTC is a feasible salvage procedure for a carefully selected subset of patients with evidence of residual ovarian function. Promoting long-term follow-up for HSCT survivors is key to identifying this critical window of opportunity and offering new hope for FP to these patients.